Home > Healthcare > Medical Devices > Diagnostic Devices > Pulmonary Fibrosis Biomarkers Market

Pulmonary Fibrosis Biomarkers Market Size

Report ID: GMI8456
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Pulmonary Fibrosis Biomarkers Market Size

Pulmonary Fibrosis Biomarkers Market size was valued at around USD 4.1 billion in 2023 and is estimated to reach over USD 6 billion by 2032. Pulmonary fibrosis biomarkers are specific molecules, substances, or characteristics found in biological samples such as blood, sputum, or lung tissue that provide valuable information about the presence, severity, progression, or response to treatment of pulmonary fibrosis.

To get key market trends

Download Free Sample

The increasing advancements in biomarker discovery technology is a significant driver for the market. For instance, according to the Prognostic Lung Fibrosis Consortium (PROLIFIC), in 2023, the identification of 12 potential prognostic, blood-based protein biomarkers helped predict the pulmonary fibrosis patient’s specific and selective requirement about the treatment regimen. This allows for the precision medicine approach and tailor treatment strategies to individuals based on their unique biomarker profiles.

Furthermore, market growth is attributed to multiple factors, including the rising prevalence of pulmonary fibrosis, growing government initiatives and policies, rising use of biomarkers, and increasing research and development in the multi-omics sector (which is estimated to reach 12.2 billion by 2032.

Pulmonary Fibrosis Biomarkers Market Report Attributes
Report Attribute	Details
Base Year:	2023
Pulmonary Fibrosis Biomarkers Market Size in 2023:	USD 4.1 Billion
Forecast Period:	2024 – 2032
Forecast Period 2024 – 2032 CAGR:	4.4%
2024 – 2032 Value Projection:	USD 6 Billion
Historical Data for:	2018 – 2023
No. of Pages:	120
Tables, Charts & Figures:	239
Segments covered:	Test Type, Indication, End-user, and Region
Growth Drivers:	Rising prevalence of pulmonary fibrosis Increasing advancements in biomarker discovery technologies Rising government initiatives and policies Increasing use of biomarkers
Pitfalls & Challenges:	High cost associated with biomarker tests and diagnostics Stringent regulatory scenario

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Pulmonary fibrosis biomarkers market size was USD 4.1 billion in 2023 and is expected to reach over USD 6 billion by 2032 owing to the increasing advancements in biomarker discovery technology worldwide.

The imaging test segment recorded USD 1.7 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to imaging tests complementing biomarker analysis and providing a comprehensive view of disease status.

North America pulmonary fibrosis biomarkers industry recorded USD 1.7 billion in 2023 due to the presence of a highly advanced healthcare infrastructure with well-established hospitals, research institutions, and diagnostic laboratories in the region.

Biocartis NV, Biogen Inc, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, Galapagos NV, Lung Therapeutics, Inc., Myriad Genetics, Inc, OptiKira LLC, Respivant Sciences GmbH, and Veracyte, Inc , are some of the major pulmonary fibrosis biomarkers companies worldwide.